How The Pieces Add Up: KOMP Targets $55
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2024
0mins
Should l Buy STVN?
Source: NASDAQ.COM
- Analyst Target Price Comparison: ETFs' holdings compared to analyst target prices, showing potential upside.
- Implied Analyst Target for KOMP: Implied analyst target price for SPDR S&P Kensho New Economies Composite ETF is $55.26 per unit.
- Notable Upside Holdings: Li Auto Inc, FingerMotion Inc, and Stevanato Group SpA have significant upside according to analysts.
- Current Analyst Target Prices: Summary table of current analyst target prices for the mentioned holdings.
- Investor Considerations: Questions about analysts' targets, optimism, and the need for further investor research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STVN
Wall Street analysts forecast STVN stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.600
Low
24.00
Averages
27.00
High
30.00
Current: 15.600
Low
24.00
Averages
27.00
High
30.00
About STVN
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Index Edges Up as Tech Stocks Rally
- Tech Stock Rally: The S&P 500 Index rose by 0.03% driven by a rebound in the Magnificent Seven tech stocks, indicating a recovery in market confidence despite ongoing uncertainties.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index was revised up to 56.4, a five-month high, exceeding expectations of 54.0, suggesting increased consumer confidence that could stimulate spending.
- Easing Inflation Expectations: The one-year inflation expectations were revised down from 4.2% to 4.0%, reflecting a reduction in market concerns about future inflation, which may support stock performance.
- Oil Price Surge: WTI crude oil prices jumped over 2% to a one-week high as President Trump reiterated military threats against Iran, boosting energy stocks and highlighting the impact of geopolitical risks on the market.
See More
S&P 500 Futures Rise in Pre-Market Session; Venture Global and Karman Holdings Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Venture Global Inc. Performance: Venture Global Inc. (VG) saw a 9.9% increase in pre-market trading.
- Karman Holdings Inc. Performance: Karman Holdings Inc. (KRMN) experienced a 9.5% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Growing Market Demand: According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, driving the need for large-volume subcutaneous drug delivery solutions, prompting Datwyler's collaboration with LTS and Stevanato to address market shifts.
- Patient Self-Administration Convenience: A Mayo Clinic study found that 73% of participants preferred in-home self-administration, highlighting the urgent demand for convenient patient-centric healthcare solutions, with Datwyler's NeoFlex™ plungers enhancing the reliability and safety of large-volume injection systems.
- Technological Innovation Showcase: The three companies will jointly present their platform solution at Pharmapack on January 21-22, 2026, aiming to optimize the development of pre-verified container closure systems, advancing technology for large-volume drug self-administration.
- Accelerated Market Access: Through collaboration, the companies will offer a pre-verified ecosystem to expedite market access, meeting stringent safety and efficacy requirements for self-administered therapies of up to 20 mL, further solidifying their market leadership in drug delivery solutions.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Market Demand Response: Datwyler's collaboration with LTS Device Technologies and Stevanato Group introduces large-volume subcutaneous drug delivery solutions, addressing the needs of 73% of patients who prefer in-home self-administration, thus facilitating a shift towards personalized healthcare at home.
- Technology Innovation Showcase: The three companies will unveil their pre-verified large-volume drug delivery platform at Pharmapack on January 21-22, 2026, aiming to accelerate market access and enhance patient medication experiences.
- Product Functionality Enhancement: Datwyler's NeoFlex™ plungers support drug delivery volumes of up to 20mL, overcoming the limitations of traditional low-volume delivery while ensuring safety and therapeutic efficacy, catering to the rapid growth of the biologics market.
- Industry Outlook: The U.S. biologics market is projected to reach $483 billion by 2034, and Datwyler's collaboration will provide innovative solutions for pharmaceutical companies, helping them maintain a competitive edge in a challenging market.
See More
SDZNY vs. STVN: Which Stock Offers Better Value?
Stock Comparison: Sandoz Group AG Sponsored ADR (SDZNY) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Stevanato Group (STVN) has a Zacks Rank of #3 (Hold), suggesting a weaker position.
Valuation Metrics: SDZNY shows a forward P/E ratio of 22.38 and a PEG ratio of 1.20, indicating better value compared to STVN's forward P/E of 34.66 and PEG ratio of 2.03.
Value Grades: Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, further supporting SDZNY as the superior value option.
Investment Recommendations: Zacks Investment Research highlights SDZNY as a strong investment opportunity, alongside other top stock recommendations with potential for significant returns.
See More
S&P 500 Futures Drop in Pre-Market Session; Oracle and Stellantis Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Ciena Corp. Performance: Ciena Corp. (CIEN) saw a 7.8% increase in pre-market trading.
Unity Software Performance: Unity Software Inc. (U) experienced a 4.7% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
S&P 500 Index Edges Up as Tech Stocks Rally
- Tech Stock Rally: The S&P 500 Index rose by 0.03% driven by a rebound in the Magnificent Seven tech stocks, indicating a recovery in market confidence despite ongoing uncertainties.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index was revised up to 56.4, a five-month high, exceeding expectations of 54.0, suggesting increased consumer confidence that could stimulate spending.
- Easing Inflation Expectations: The one-year inflation expectations were revised down from 4.2% to 4.0%, reflecting a reduction in market concerns about future inflation, which may support stock performance.
- Oil Price Surge: WTI crude oil prices jumped over 2% to a one-week high as President Trump reiterated military threats against Iran, boosting energy stocks and highlighting the impact of geopolitical risks on the market.
See More
S&P 500 Futures Rise in Pre-Market Session; Venture Global and Karman Holdings Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Venture Global Inc. Performance: Venture Global Inc. (VG) saw a 9.9% increase in pre-market trading.
- Karman Holdings Inc. Performance: Karman Holdings Inc. (KRMN) experienced a 9.5% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Growing Market Demand: According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, driving the need for large-volume subcutaneous drug delivery solutions, prompting Datwyler's collaboration with LTS and Stevanato to address market shifts.
- Patient Self-Administration Convenience: A Mayo Clinic study found that 73% of participants preferred in-home self-administration, highlighting the urgent demand for convenient patient-centric healthcare solutions, with Datwyler's NeoFlex™ plungers enhancing the reliability and safety of large-volume injection systems.
- Technological Innovation Showcase: The three companies will jointly present their platform solution at Pharmapack on January 21-22, 2026, aiming to optimize the development of pre-verified container closure systems, advancing technology for large-volume drug self-administration.
- Accelerated Market Access: Through collaboration, the companies will offer a pre-verified ecosystem to expedite market access, meeting stringent safety and efficacy requirements for self-administered therapies of up to 20 mL, further solidifying their market leadership in drug delivery solutions.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Market Demand Response: Datwyler's collaboration with LTS Device Technologies and Stevanato Group introduces large-volume subcutaneous drug delivery solutions, addressing the needs of 73% of patients who prefer in-home self-administration, thus facilitating a shift towards personalized healthcare at home.
- Technology Innovation Showcase: The three companies will unveil their pre-verified large-volume drug delivery platform at Pharmapack on January 21-22, 2026, aiming to accelerate market access and enhance patient medication experiences.
- Product Functionality Enhancement: Datwyler's NeoFlex™ plungers support drug delivery volumes of up to 20mL, overcoming the limitations of traditional low-volume delivery while ensuring safety and therapeutic efficacy, catering to the rapid growth of the biologics market.
- Industry Outlook: The U.S. biologics market is projected to reach $483 billion by 2034, and Datwyler's collaboration will provide innovative solutions for pharmaceutical companies, helping them maintain a competitive edge in a challenging market.
See More
SDZNY vs. STVN: Which Stock Offers Better Value?
Stock Comparison: Sandoz Group AG Sponsored ADR (SDZNY) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Stevanato Group (STVN) has a Zacks Rank of #3 (Hold), suggesting a weaker position.
Valuation Metrics: SDZNY shows a forward P/E ratio of 22.38 and a PEG ratio of 1.20, indicating better value compared to STVN's forward P/E of 34.66 and PEG ratio of 2.03.
Value Grades: Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, further supporting SDZNY as the superior value option.
Investment Recommendations: Zacks Investment Research highlights SDZNY as a strong investment opportunity, alongside other top stock recommendations with potential for significant returns.
See More
S&P 500 Futures Drop in Pre-Market Session; Oracle and Stellantis Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Ciena Corp. Performance: Ciena Corp. (CIEN) saw a 7.8% increase in pre-market trading.
Unity Software Performance: Unity Software Inc. (U) experienced a 4.7% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
